Presentations will be delivered by experts from a wide variety of leading research groups including Pfizer, GSK, and Bio-Techne, along with co-hosts IPA, ACROBiosystems, and Curia. SALT LAKE CITY, ...

In-Licensing of novel activin E antibody underscores iBio’s commitment to delivering meaningful benefits to patients living ...

Phase 1 trial of TGW101 in advanced solid tumors is enrolling to assess safety and pharmacokinetics and define the maximum ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Irritable bowel syndrome, chronic itching, asthma and migraine are in many cases hard-to-treat conditions. They have in ...

Another reason for choosing a particular modality is that it is a team’s specialty. Strategic choices can be less about determining which modality best fits a potential target than about choosing a ...

New research suggests that lingering cell wall fragments from the Lyme disease bacterium, Borrelia burgdorferi, may be responsible for persistent symptoms long after antibiotic treatment.

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody isotopes for cancer.

Scientists believe they know what causes the treated infection to mimic chronic illness: the body may be responding to remnants of the bacteria that causes Lyme that tend to pool in the liver and ...

Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeutics Focus on breakthrough ADC payloads and ...